Oncology Drugs - Jordan

Jordan

In Jordan, the Oncology Drugs market is expected to witness a significant increase in revenue, reaching US$56.48m by 2024.
The market is projected to experience a steady annual growth rate (CAGR 2024-2029) of 6.62%, leading to a market volume of US$77.81m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, amounting to US$103,900.00m in 2024.
Jordan is experiencing a surge in the demand for innovative oncology drugs, driven by a growing population and increasing prevalence of cancer.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for oncology drugs in Jordan has been increasing steadily over the years.

Customer preferences: Jordan has a high prevalence of cancer, and as a result, the demand for oncology drugs has been on the rise. Patients in Jordan prefer innovative and effective cancer treatments that can help improve their quality of life. They are also increasingly opting for personalized medicine that is tailored to their specific genetic makeup.

Trends in the market: The oncology drugs market in Jordan is witnessing a shift towards targeted therapies and immunotherapies. These treatments are more effective and have fewer side effects compared to traditional chemotherapy. The market is also witnessing an increasing number of partnerships between local and international pharmaceutical companies to improve the availability of oncology drugs in the country.

Local special circumstances: Jordan has a high burden of non-communicable diseases, including cancer. The government has taken several initiatives to improve cancer care in the country, including the establishment of specialized cancer centers and the provision of free cancer treatment to eligible patients. However, the country still faces challenges in terms of access to oncology drugs, particularly in rural areas.

Underlying macroeconomic factors: The Jordanian economy has been growing steadily over the years, driven by the services sector. The healthcare sector is also growing, with the government investing in healthcare infrastructure and improving access to healthcare services. However, the country faces challenges in terms of high unemployment rates and dependence on foreign aid. These factors can impact the affordability of oncology drugs for patients in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.